Pandemic Debate

Ernest Ramirez, father from Austin, TX whose only son collapsed playing basketball and passed away from myocarditis following Pfizer vaccination Tuesday, Nov. 2 / Panel discussion on vaccine mandates and the consequences and the lack of compassion and response from federal health agencies to those who have experienced adverse events from the COVID-19 vaccine

Lt. Col. Colonel Theresa Long MD, Brigade Surgeon for the 1st Aviation Brigade, Ft. Rucker, Alabama, US Army - Whistleblower for CV-19 malfeasance Tuesday, Nov. 2 / Panel discussion on vaccine mandates and the consequences and the lack of compassion and response from federal health agencies to those who have experienced adverse events from the COVID-19 vaccine

Profile from University of Guelph website Dr. Bridle is a viral immunologist who is passionate about improving life through two avenues of research. One arm of his research program is dedicated to designing and optimizing novel biotherapies for the treatment of cancers. The goal of his research team is to harness the natural power of a patient's immune system to eliminate their own cancer cells. This represents the ultimate personalized therapy and holds the potential to treat cancers more effectively, safely, and at lower cost than current options. The second arm of his research program focuses on studying host responses to viruses and other inflammatory stimuli. This has implications for the treatment of infectious diseases and inflammation-mediated disorders. These two programs have been unified in a unique way. The Bridle lab is harnessing their expertise in making potent cancer vaccines and combining this with their interest in anti-viral immunity to develop vaccines to protect against infectious diseases such as those caused by highly pathogenic coronaviruses. Mentoring the next generation of Canadian scientists is a responsibility that Dr. Bridle takes very seriously. He also counts it a privilege to teach students in the Doctor of Veterinary Medicine, graduate and undergraduate programs at the University of Guelph. Research Interests The research program in the Bridle lab has two arms. One is to develop novel, highly targeted biotherapies for the treatment of cancers. In an effort to kill malignant cells with minimal bystander damage to normal tissues, two approaches are combined: (a) cancer immunotherapy that directs the power of a patient’s immune system against their own tumour(s) and, (b) oncolytic virotherapy, which utilizes viruses that replicate in and kill only cancerous cells. The exquisite specificity, systemic targeting capability and short treatment windows of these therapies hold promise that cancer patients might be effectively treated with reduced side-effects and at minimal cost. The goal is to translate the most promising iterations of these therapies into clinical trials in companion animals as a stepping stone towards testing in human patients. A second emphasis of the lab is the study of host responses to viruses. An area of focus is developing a better understanding of the mechanisms underlying virus-induced cytokine storms. Dr. Bridle's research team has identified a critical role of signaling through the type I interferon receptor in the negative regulation of an extensive network of cytokines. Cytokine responses to viruses are often very different between females and males and the Bridle lab group is seeking to understand why. At the intersection of these two programs, is a research initiative aimed at modifying the research team's optimized cancer vaccine platforms to target severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which is the causative agent of the coronavirus disease identified at the end of 2019 (COVID-19). The long-term goal is to have a flexible technological platform to rapidly develop vaccines against highly pathogenic coronaviruses that may emerge in the future. The Bridle lab seeks researchers who are collaborative, highly motivated, innovative, hard-working and want to have a significant impact in the field of viral immunology. An outstanding academic record, excellent writing and oral presentation skills and a collaborative approach are essential. Trainees will have an opportunity to gain valuable, hands-on research experience in a variety of areas. Learning the fundamental principles of immunology, cancer biology and/or virology is an emphasis. Applicants who are willing to work longer hours than average, are passionate about pursuing a career in research, are excellent communicators, punctual, autonomous and possess excellent technical skills will excel in this laboratory. In return, members can expect diligent mentorship, access to state-of-the-art research resources, with opportunities spanning the basic to translational research spectrum, giving them the resources needed to potentially publish in the highest impact scientific journals and placing the future of their research career in their own hands. Prospective trainees should submit a curriculum vitae, transcripts (unofficial copies would suffice) and a cover letter explaining how they could help advance the research mandates of this laboratory. Research Funding: The Bridle lab is or has been funded by: Canadian Institutes of Health Research Natural Sciences and Engineering Research Council of Canada (NSERC) Terry Fox Research Institute Canadian Cancer Society, Cancer Research Society Canadian Breast Cancer Foundation Ontario COVID-19 Rapid Reserach Fund University of Guelph/Ontario Veterinary College/Department of Pathobiology COVID-19 Seed Funding National Centre of Excellence in Biotherapeutics for Cancer Treatment (BioCanRx) OVC Pet Trust The Smiling Blue Skies Cancer Fund Canadian Foundation for Innovation - John R. Evans Leaders Fund Canadian Foundation for Innovation - Infrastructure Operating Funds Ministry of Research and Innovation Ontario Research Fund - Research Infrastructure Program The Bridle lab is part of the… Canadian Oncolytic Virus Consortium Network of Centre of Excellence in Biotherapies for Cancer Treatment (founding member) Canadian Society for Immunology Canadian Society for Virology Terry Fox Research Institute Institute for Comparative Cancer Investigation Dog Osteosarcoma Group: Biomarkers/Biotherapy Of Neoplasia (DOGBONe) One Health Institute Teaching VETM*3080 Veterinary Physiology and Biochemistry (Head Instructor: Veterinary Immunology) VETM*3450 Principles of Disease in Veterinary Medicine (Immunology Review Lecture) BIOM*4150/6702 Cancer Biology (Tumour Immunology Unit) BIOM*6800 Gene Expression in Health and Disease (Lecture: “Identification of genes encoding tumour-associated antigens and their use in cancer vaccine design”) PABI*6104 Mechanisms of Disease (Lecture: “Oncolytic and Immunotherapies”) BIOM*4521/2 Research in Biomedical Sciences BIOM 4500 Research in Biomedical Sciences Literature Review HK*4371/2 Research in Human Biology and Nutritional Sciences TOX*4900/10 Research Project PABI*6960 Special Topics in Pathobiology CLIN*6560 - Small Animal Internal Medicine II (Immunology Review Lecture) Professional Experience & Honours Dr. Bridle received graduate training in immunology at the University of Guelph and then postdoctoral training as a viral immunologist at McMaster University. Some of Dr. Bridle's noteworthy honours include: The Carl J. Norden Distinguished Teaching Award. This is the highest teaching award given by each North American Veterinary College; the recipient is chosen based on a vote of the second, third and fourth year veterinary classes. Terry Fox Research Institute New Investigator Award Being elected to be an honourary class president for the Ontario Veterinary College's Doctor of Veterinary Medicine classes of 2017 (Violet Komodos) and 2023 (Opal Otters) Zoetis Award for Research Excellence

ABOUT DR. McCULLOUGH: Dr. McCullough is board certified in internal medicine, cardiovascular diseases, and clinical lipidology. He cares for advanced patients with common medical problems including heart and kidney disease, lipid disorders, and diabetes. He has become an expert on COVID-19 illnesses and welcomes recovered patients into his practice. To inquire on Covid-19 related questions, email pmccovid2021@gmail.com After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan. Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 600 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the editor-in-chief of Reviews in Cardiovascular Medicine and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), and the European Medicines Agency. He has served as member or chair of data safety monitoring boards of 24 randomized clinical trials. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 35 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs concerning early ambulatory treatment of high-risk patients with COVID-19. Dr. McCullough is a COVID-19 survivor himself and welcomes post-COVID-19 patients into his practice and will help them through the range of post-infection complications. BOARD CERTIFICATIONS: Cardiovascular Disease Advanced Lipidology Internal Medicine HOSPITALS: Baylor Scott & White Heart and Vascular Hospital - Dallas * Fort Worth Baylor University Medical Center CLINIC LOCATIONS: HeartPlace Baylor Heart & Vascular Hospital-BHVH Office: (214) 841-2000 Fax: (844) 292-1458 3409 Worth Street Suite 500 Dallas, TX 75246

Peter McCullough, MD, MPH speaks at the 78th Annual Meeting of the Association of American Physicians and Surgeons on October 2, 2021 ABOUT DR. McCULLOUGH: Dr. McCullough is board certified in internal medicine, cardiovascular diseases, and clinical lipidology. He cares for advanced patients with common medical problems including heart and kidney disease, lipid disorders, and diabetes. He has become an expert on COVID-19 illnesses and welcomes recovered patients into his practice. To inquire on Covid-19 related questions, email pmccovid2021@gmail.com After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan. Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 600 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the editor-in-chief of Reviews in Cardiovascular Medicine and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), and the European Medicines Agency. He has served as member or chair of data safety monitoring boards of 24 randomized clinical trials. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 35 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs concerning early ambulatory treatment of high-risk patients with COVID-19. Dr. McCullough is a COVID-19 survivor himself and welcomes post-COVID-19 patients into his practice and will help them through the range of post-infection complications. BOARD CERTIFICATIONS: Cardiovascular Disease Advanced Lipidology Internal Medicine HOSPITALS: Baylor Scott & White Heart and Vascular Hospital - Dallas * Fort Worth Baylor University Medical Center CLINIC LOCATIONS: HeartPlace Baylor Heart & Vascular Hospital-BHVH Office: (214) 841-2000 Fax: (844) 292-1458 3409 Worth Street Suite 500 Dallas, TX 75246

Dr Daniel Nagase battles Alberta authorities to treat his patients with Ivermectin in Red Deer "It is wonderful to see all of you here remembering Nuremburg. And that’s the key here, remembering. Not just the nurses and doctors that are helping by speaking the Truth, people like Dr. Charles Hoffe in Lytton, But also to remember the doctors in hospital administration, the doctors at the college of physicians and surgeons, the doctors you see on TV that are standing in the way of life saving medicaitons, Let me tell you what happened in Rimbey Alberta, a small town couple hours west of Red Deer. It shocked me. I started on Saturday morning in the ER, and when it came time to round on the ward patients, the charge nurse informed me that 3 of the patients on the COVID wing had deteriorated overnight. All the patients were on Oxygen and extremely short of breath. The only medication these patients were on were steroids. A Medication that will decrease inflammation but increase the chances of a bacterial infection by suppressing the immune system. That’s right, the only medication the covid patients at this hospital were on were immune suppressants. One woman said it felt like we just put her in a corner to die. We weren’t doing anything for her. I told her, I can’t speak for the usual doctors during the week, but it’s the weekend, and I’ll do everything I can to help. I offered Ivermectin. She wanted to try it because she heard nothing but good things about it. All 3 patients wanted to try ivermectin. The hospital didn’t have any, so we had to ask Red Deer Hospital’s Central Pharmacy for the medication. They refused to send Ivermectin. Red Deer’s central pharmacist said Ivermectin was useless for COVID. He even had the Pharmacy Director for All of Alberta contact me to tell me Ivermectin didn’t work. The Pharmacy Director for Alberta Health services is Dr. Gerald Lazarenko. Remember that name. He is both a Pharmacist and a Doctor. And he insisted that Ivermectin had no place in the treatment of COVID. So we checked the local pharmacies. And God bless that charge nurse, although both pharmacies in town did not have ivermectin, there was one pharmacist who would do everything he could to get some even if it took all day. We didn’t have all day, my patients were sick. So I started everyone on the next best thing, Hydroxychloroquine which the hospital did have. I also started Vitamin C, Vitamin D, and Zinc. And because the patients were coughing and short of breath I gave them inhalers… Salbutamol and Flovent, the same inhalers that have been used for asthma for over 50 years. I also gave them Azithromycin. Surprisingly by late afternoon, the town pharmacist finally found some ivermectin. He couldn’t get it from his usual chemical supply, because it was a Saturday. He had to get it from an agricultural supply. He checked to make sure that it was the exact same Ivermectin a pharmacist would give to a person, brought it back to his pharmacy and checked it again. He then called me with the good news. I handed Ivermectin to each of my 3 patients with their exact dose of according to their weight. And you’ll never guess what happened next. Within hours of getting Ivermectin, I got a call from the Central Zone medical director. Dr Jennifer Bestard. She called me to tell me I was forbidden from giving Ivermectin to patients. I told her she’s never met the patients, she’s not their doctor, and had no right to be changing the care of my patients without the patient’s permission. She said Ivermectin was forbidden from the hospital. Even if the patients had their own Ivermectin. (Which I would have happily given to a relative so they could to hand it over to them), Patients would not be allowed to take their own ivermectin. She said it was a violation of Alberta Health Services Policy to give Ivermectin for COVID. But that wasn’t good enough. The next day she called the hospital and gave me 15 minutes notice that I would be relieved of my duties. I told her that it was unreasonable. I had an emergency department full of patients who can’t be sorted out in 15 minutes. An hour later another local doctor came to replace me. They didn’t even want me to check up on the patients who I gave Ivermectin to. Not even 24 hours after getting Ivermectin, 2 out of my 3 patients were almost completely better. They were out of bed walking around and all the crackles I heard in their lungs from the day before were gone. All it took was about 18 hours and 1 dose of Ivermectin. The third patient who was 95 years old, stayed the same. She didn’t get any worse like she had done the night previous. I found out later that no sooner had I left Rimbey hospital, the next doctor who came to replace me stopped the antibiotics, stopped all the vitamins, she even stopped the patients inhalers. Within hours of my leaving the hospital this doctor even took away the patient’s inhalers, to help her breathe. The patients were not even allowed vitamins. Thankfully, both my 70 year old patients who had immediate recoveries after a single dose of ivermectin left the hospital that week. (I’d like to speak briefly to the healthcare professionals in the crowd) No doctor would take away antibiotics and inhalers for ANY viral pneumonia, never mind COVID. No doctor would do that to ANY patient with a pneumonia. Unless they were… Well I’ll let you think about that. We are remembering Nuremburg after all. And for healthcare professionals, I want us all to think very deeply about that. But it gets worse, In my brief day and a half in the small town of Rimbey, I saw 2 patients who had recently been discharged from Red Deer Hospital after being on the COVID ward. They were sent home with NOTHING. Not even an inhaler. These patients ended up in ER at a small hospital wanting help. Just days after being sent home from a tertiary care hospital with nothing. There is something malicious going on. I hope you can all see the bigger picture. This is more than me having all my assignments to take care of small communities cancelled for the rest of the year. This is more than the medical director, Dr. Fraincois Belanger banning me from hospital practice throughout all of Alberta. Just a week after giving ivermectin and then filing a complaint against the Alberta Pharmacy Director, a complaint sent to the College of Physicians and Surgeons, about the Pharmacy director for an entire province denying 11 pages of studies showing 0% mortality for patients given Ivermectin. In study after study after study, 0% mortality, 0% mortality, 0% mortality… with Ivermectin. And in “Severe” COVID? A 50% reduction in mortality with Ivermectin. This is all in Albertat Health Services own Ivermectin report. Just a week after I filed a complaint that Dr. Gerald Lazarenko was withholding a life saving medication from an entire province, the Alberta college of physicians and Surgeons forbade doctors and pharmacists from giving patients ivermectin. We must remember. We are here to remember. Not just the people who died from medical experimentation. We are here to remember the people today. We are here to remember every single doctor, lawyer, and medical ethicist that sits on the board of the BC college who is investigating Dr. Charles Hoffe for speakng the truth. We are here to remember every doctor who stopped patients from having a live saving medication. And what for? To boost mortality? To create an ICU “crisis”? To create a state of emergency? All to push a vaccine? We must remember, the people of the past. And the people of today. History repeats itself. Nuremburg will happen again. We must remember."

Div 1 Tennessee State Golfer has his career destroyed by the COVID VACCINE, diagnosed with Myocarditis and Pericarditis 4 days after receiving the vaccine

“I Don’t Care. We’re Vaccinated Enough!”

Sept 2021

Project Veritas Whistleblowers

Original source of video is on the FDA youtube channel

Martin Kulldorff, PhD, is a Professor of Medicine at Harvard Medical School. His research centers on developing new epidemiological and statistical methods for the early detection and monitoring of infectious disease outbreaks and for post-market drug and vaccine safety surveillance.

Texas Senate March 2021

College threatening to take away his Doctor's license for speaking out against public health officials

Dr Charles Hoffe from Lytton BC discovers blood clotting in his patients after Covid 19 Vaccine

After contact with Public Health Official regarding patients having blood clots after vaccine

Dr Byram Bridle - Career destroyed for speaking out against Covid Vaccine

Dr Bret Weinstein Darkhorse Podcast

Mt. Vernon school board meeting in Indiana on August 6, 2021

Zelenko Protocols against Covid-19 - Zelenko Protocol innovator: 99% survival of high risk Covid-19 patients - Nominated for the Presidential Medal of Freedom - Recognized as a hero at U.S. Senate Homeland Security committee hearing - Published in top peer reviewed journals with world renowned physicians - Provided counsel to White House personnel, multiple governments, hospitals, physicians, public figures - Board Certified Family Physician with over 20 years experience

Dr. Ryan Cole, M.D. is a board certified anatomic pathologist. Dr. Cole spoke at the White Coat Summit hosted by America’s Frontline Doctors. Check out his presentation on what the experimental jabs are doing to the human body.

Dr Michael Yeadon earned his undergraduate degree in biochemistry and toxicology, and his PhD in respiratory pharmacology. He has worked for 32 years in the pharmaceutical industry and 10 years in biotechnology. He was the Vice President and Chief Scientist of Allergy and Respiratory Research for Pfizer until 2011. Mike then founded and grew his own biotech company and sold it to Novartis in 2017. He has been an independent advisor to more than 30 startup biotech companies.

DR. RYAN N. COLE – DIRECTOR OF COLE MEDICAL DIAGNOSTICS LABORATORY – IDAHO “Dr. Cole is a board-certified dermatopathologist (AP & CP) and the CEO/Medical Director of Cole Diagnostics. He has worked as an independent pathologist since 2004. Some highlights from his CV: Ackerman Academy of Dermatopathology (July 2002-June 2003): Dermatopathology Fellowship (Chief Fellow). Mayo Clinic (July 1997-June 2002): Resident in Anatomic and Clinical Pathology. Chief Fellow, Surgical Pathology Fellowship. Medical College of Virginia (1993-1997): Researched immunology. Served as President of Student Family Practice organization. Coordinated activities and seminars on the practice of family medicine and rural medicine. Earned MD in 1997.” Dr. Cole has treated 350,000 patients during his career and has performed 100,000 COVID tests this last year.